Leah Cann
Stock Analyst at Brookline Capital
(1.78)
# 1,866
Out of 4,479 analysts
11
Total ratings
42.86%
Success rate
57.14%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEIP MEI Pharma | Maintains: Buy | $80 | $2.80 | +2,757.14% | 2 | May 23, 2023 | |
| CRBU Caribou Biosciences | Initiates: Buy | $19 | $1.60 | +1,087.50% | 1 | Feb 14, 2022 | |
| AGIO Agios Pharmaceuticals | Assumes: Perform | n/a | $42.05 | - | 2 | Feb 20, 2019 | |
| EXEL Exelixis | Upgrades: Outperform | n/a | $22.15 | - | 2 | Feb 27, 2018 | |
| NTLA Intellia Therapeutics | Initiates: Perform | n/a | $22.15 | - | 1 | Jul 18, 2017 | |
| EDIT Editas Medicine | Initiates: Perform | n/a | $4.54 | - | 1 | Jul 18, 2017 | |
| CRSP CRISPR Therapeutics AG | Initiates: Perform | n/a | $53.12 | - | 1 | Jul 18, 2017 | |
| VSTM Verastem | Initiates: Outperform | n/a | $2.94 | - | 1 | Apr 13, 2017 |
MEI Pharma
May 23, 2023
Maintains: Buy
Price Target: $80
Current: $2.80
Upside: +2,757.14%
Caribou Biosciences
Feb 14, 2022
Initiates: Buy
Price Target: $19
Current: $1.60
Upside: +1,087.50%
Agios Pharmaceuticals
Feb 20, 2019
Assumes: Perform
Price Target: n/a
Current: $42.05
Upside: -
Exelixis
Feb 27, 2018
Upgrades: Outperform
Price Target: n/a
Current: $22.15
Upside: -
Intellia Therapeutics
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $22.15
Upside: -
Editas Medicine
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $4.54
Upside: -
CRISPR Therapeutics AG
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $53.12
Upside: -
Verastem
Apr 13, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.94
Upside: -